Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Leflunomide and malononitrilamides

H T Silva Júnior1, R E Morris

  • 1Nephrology Division, Escola Paulista de Medicina, São Paulo, Brazil.

The American Journal of the Medical Sciences
|May 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unveiling MOF-808 photocycle and its interaction with luminescent guests.

Physical chemistry chemical physics : PCCP·2024
Same author

Nature of the Spin Liquid Ground State in a Breathing Kagome Compound Studied by NMR and Series Expansion.

Physical review letters·2017
Same author

Structural analysis of IPC zeolites and related materials using positron annihilation spectroscopy and high-resolution argon adsorption.

Physical chemistry chemical physics : PCCP·2016
Same author

Developing New Immunosuppression for the Next Generation of Transplant Recipients: The Path Forward.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

PP090. The contribution of podocyturia to the evaluation of ongoing glomerular disorder in pregnant women with kidney graft (preliminary results).

Pregnancy hypertension·2015
Same author

The avidin-biotin system.

Immunology today·2014

Leflunomide, an immunomodulatory drug, effectively treats rheumatoid arthritis by inhibiting T- and B-cell activity. Further research is exploring its metabolite A77 1726 and analogues for transplantation and autoimmune diseases.

Area of Science:

  • Immunology
  • Pharmacology
  • Rheumatology

Background:

  • Leflunomide is an immunomodulatory drug with demonstrated efficacy in autoimmune disease models and transplantation.
  • Its primary active metabolite, A77 1726, is a malononitrilamide responsible for its therapeutic effects.
  • The precise mechanisms of action for malononitrilamides are still under investigation.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of leflunomide in patients with advanced rheumatoid arthritis.
  • To explore the mechanisms of action of leflunomide and its metabolite A77 1726.
  • To investigate novel malononitrilamide analogues for immunosuppressive applications in transplantation.

Main Methods:

  • Phase II clinical trials assessed leflunomide's efficacy and tolerability in rheumatoid arthritis patients.

Related Experiment Videos

  • In vitro and in vivo studies examined the effects of malononitrilamides on immune cells.
  • Preclinical models are evaluating the immunosuppressive potential of A77 1726 analogues.

    • Main Results:

    • Leflunomide demonstrated high tolerability and efficacy in patients with advanced rheumatoid arthritis at daily doses of 10 mg and 25 mg.
    • A77 1726 inhibits T- and B-cell proliferation, immunoglobulin production, and cell adhesion, potentially through inhibiting de novo pyrimidine biosynthesis and tyrosine kinase activity.
    • Higher doses of leflunomide increased adverse effects, including gastrointestinal issues and rash.

    Conclusions:

    • Leflunomide is an effective treatment for active rheumatoid arthritis.
    • Ongoing Phase III trials aim to confirm leflunomide's efficacy and safety.
    • Malononitrilamide analogues are being developed as potential immunosuppressants for organ transplantation.